within Pharmacolibrary.Drugs.V_Various.V03A_AllOtherTherapeuticProducts.V03AB32_Glutathione;

model Glutathione
  extends Pharmacolibrary.Drugs.ATC.V.V03AB32;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>V03AB32</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Glutathione is a tripeptide composed of glutamine, cysteine, and glycine. It acts as an important endogenous antioxidant, protecting cells from oxidative stress and maintaining cellular redox balance. Glutathione has been used experimentally as a dietary supplement or adjunctive medication in conditions involving oxidative stress, including liver disease, neurodegenerative disorders, and as an antidote for acetaminophen toxicity. It is not widely approved by regulatory authorities for intravenous use, but is available as a supplement.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for healthy adults after intravenous administration, as no standard population PK parameters are comprehensively published.</p><h4>References</h4><ol><li><p>Forrest, JA, et al., &amp; Prescott, LF (1982). Clinical pharmacokinetics of paracetamol. <i>Clinical pharmacokinetics</i> 7(2) 93–107. DOI:<a href=\"https://doi.org/10.2165/00003088-198207020-00001\">10.2165/00003088-198207020-00001</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/7039926/\">https://pubmed.ncbi.nlm.nih.gov/7039926</a></p></li><li><p>Lawson, R, et al., &amp; Hennig, S (2021). Review of the Pharmacokinetics and Pharmacodynamics of Intravenous Busulfan in Paediatric Patients. <i>Clinical pharmacokinetics</i> 60(1) 17–51. DOI:<a href=\"https://doi.org/10.1007/s40262-020-00947-2\">10.1007/s40262-020-00947-2</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33128207/\">https://pubmed.ncbi.nlm.nih.gov/33128207</a></p></li><li><p>Aebi, S, et al., &amp; Lauterburg, BH (1991). High-dose intravenous glutathione in man. Pharmacokinetics and effects on cyst(e)ine in plasma and urine. <i>European journal of clinical investigation</i> 21(1) 103–110. DOI:<a href=\"https://doi.org/10.1111/j.1365-2362.1991.tb01366.x\">10.1111/j.1365-2362.1991.tb01366.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/1907548/\">https://pubmed.ncbi.nlm.nih.gov/1907548</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Glutathione;
